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Background
As rare myelomas, i.e. the IgD, IgE, IgM and non-secretory forms, constitute only a small pro-
portion of any study, relatively little is known about their prognosis in the era of peripheral
stem cell transplantation.
Design and Methods
We used the European Group for Blood and Marrow Transplantation Myeloma Database to
compare the outcome following autologous transplantation of over 20,000 patients with com-
mon myelomas (IgG, IgA and light chain myeloma) with the outcome of patients with rare
myelomas: 379 IgD, 13 IgE, 72 IgM and 976 non-secretory cases.  
Results
The study confirms the multiple adverse prognostic factors seen in IgD myeloma.  Somewhat
surprisingly, patients with IgD and non-secretory myeloma both had higher complete remis-
sion rates before and after transplantation than patients with common myelomas. However,
while the overall survival of patients with non-secretory myeloma was similar to that of the
patients with common myelomas, the survival of patients with IgD myeloma was significantly
worse (although better than survival rates reported for non-transplanted patients); this was due
to higher transplant-related mortality and relapse/progression rates. The post-transplantation
survival of patients with IgE or IgM myeloma appears to be very poor.  
Conclusions
This study provides data on the biological features of rare myelomas. The overall survival of
patients with IgD, IgE or IgM myeloma is poor following autologous transplantation but sub-
stantially better than that reported for patients who were not transplanted. 
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Introduction
More than 90% of myelomas will have IgG, IgA or
Bence-Jones protein only ideotypes. IgD and non-secreto-
ry myelomas are uncommon while IgM and IgE myelo-
mas are rare or extremely rare.1 Survival of patients with
IgD myeloma is generally accepted to be poorer than that
of patients with ‘common’ myelomas.2-5 The situation for
non-secretory myeloma is less clear; originally thought to
confer an adverse prognosis the majority of authorities
now suggest that the prognosis of patients with this form
of myeloma is similar6-8 to or possibly better9,10 than that
of patients with common myelomas. It should be noted
that these results are based on only small numbers of
cases in the series reported. It would also seem that the
survival of patients with IgE or IgM myeloma treated
with standard therapy may be somewhat shorter than
that of patients with the ‘common’ myelomas. 
Little is known about the impact of conventional trans-
plant strategies on the outcome of any of the rare myelo-
mas. The introduction of alternative strategies for allo-
geneic transplantation with low intensity conditioning,
inclusion of new drugs in autologous approaches and
new non-transplant therapeutic modalities may improve
the outlook for all myeloma patients. It is, therefore, an
opportune time to review the outcome of conventional
transplantation strategies on the rare myelomas when
compared with a group of common myelomas. In this
study we used the myeloma database of the European
Group for Blood and Marrow Transplantation (EBMT) to
study the outcome of autologous transplantation in
patients with IgD, IgE, IgM or non-secretory myeloma
and compared these patients’ outcome with that of over
20,000 patients with common myelomas.
Design and Methods
A retrospective study was carried out of 22,244 patients with
multiple myeloma who underwent autologous transplantation
between 1986 and 2007 and for whom complete data on age,
sex and type of myeloma were available. Half of the patients
were transplanted after the year 2000. The numbers of patients
with each type of myeloma are shown in Table 1. Patients with
IgG, IgA or Bence-Jones myeloma were collectively described as
having ‘common’ myeloma. Patients with plasma cell leukemia
were analyzed in a concurrent analysis.11 Cases with solitary
plasmacytoma and amyloidosis were also excluded. All patients
were reported to the EBMT registry using MED-A (limited data
set) or MED-B (more extensive data set) forms. All 22,444 auto-
grafted patients were included in the study, regardless of avail-
ability of complete MED-A or MED-B data. The number of
patients that could be evaluated for each parameter was noted
and the proportion of evaluable patients is included in the
results. Factors known to affect the transplant outcome from
previous EBMT studies12 were also analyzed.
Statistical methods
Groups were compared using the χ2 test for frequencies and
the Mann-Whitney test for continuous variables. Survival curves
were generated according to the Kaplan-Meier method and dif-
ferences were tested with the log-rank test. Cumulative inci-
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Table 1. Characteristics of patients with the common types of myeloma and with non-secretory, IgD, IgM or IgE myeloma (n=22244).
Patients’ Common myelomas Data IgD Data IgE Data IgM Data Non Data 
characteristics IgG n=12245 (55%) available % n=379 available % n=13 available % n=72 available % secretory available %
IgA n=4533 (20%) (1.7%) (0.1%) (0.3%) n=976 
BJP n=4026 (18%) (4.4%)
Gender %* male 58.2* 100 64.9* 100 76.9 100 62.5 100 56.2* 100
Age†† years 55.6 100 54.3 100 54.6 100 56.2 100 54.4 100
Albumin† g/L 37.0 15.4 40.5 12.7 41 7.7 35 12.5 40.0 12.7
Calcium† mmol/L 2.38 28.4 2.48 23.0 2.3 15.4 2.75 15.2 2.42 17.1 
Creatinine† mmol/L 92.0 26.5 130.5 23.7 65 15.4 85 15.2 80.0 16.6
Hemoglobin† g/dL 11.0 31.7 10.1 25.9 11.8 23.1 9.35 19.4 12.1 (23.0)
B2 microglobulin† mg/L 3.1 21.8 4.4 20.6 5.4 15.4 3.3 15.2 2.6 (18.6)
Time to transplantation† months 7.7 100 6.9 100 6.9 100 7.6 100 7.6 (100)
Durie-Salmon stage I 13.2 6.4 10 6.3 6.9
(at diagnosis)** II 20.5 80.7 16.8 75.2 40 76 19.0 87 18.0 79.0
III 66.3 76.8 50 74.6 75.1
Bone ** (structure normal 23.8 17.3 25 12.8 7.1
at diagnosis)
Light chain type** κ 65.5 100 24.7 75.7 40 76 70.9 76 N/A
λ 34.5 75.3 60 29.1 N/A
Graft source** PBSC 96.9 96.2 84.6 95.7 95.7
BM 2.0 98.4 3.5 98.4 15.4 4.3 3.1
BM and PBSC 1.1 0.3 0 100 7.0 97.2 1.2 98.4
Use of TBI†† no 92.2 86.5 84.6 98.5 94.5
yes 7.8 94.2 13.5 93.7 15.4 100 1.5 97.7 5.5 94.7
Conditioning for melphalan 75.7 46.9 64.8 44.3 60.0 87.5 73.6
transplantation†† other 24.3 35.2 20.0 12.4 26.4
*P<0.018 for IgD/non-secretory myeloma as a discrete variable, **P<0.001 for IgD/non-secretory myeloma discrete variables, †P<0.001 for IgD/non-secretory myeloma continuous vari-
ables, ††P<0.0001 for IgD/non-secretory myeloma. TBI: total body irradiation; PBSC: peripheral blood stem cells; BM: bone marrow; BJP: Bence-Jones protein.
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dence curves were produced using the proper non-parametric
estimator, and Gray’s test was used for comparisons. Adjusted
effects on overall survival, progression-free survival, relapse inci-
dence and non-relapse mortality were estimated in terms of haz-
ard ratios by Cox models. Adjusted effects on response were
estimated in terms of odds ratios by logistic regression; the con-
stant term represents the baseline odds ratio, that is the ratio
between probability of response and probability of no response
for a patient with all covariates equal to zero. The adjustment
factors considered in the multivariable models were age, gender,
disease stage at diagnosis, use of total body irradiation (TBI),
interval from diagnosis to transplant and, except for patients
with non-secretory myeloma, the light chain type.  Overall
16,956 (76%) cases with complete patterns of covariates were
included: 15,959 with common myelomas, 215 with IgD myelo-
ma, 47 with IgM myeloma and 735 with non-secretory myelo-
ma. These proportions were similar to those in the whole group.
Patients with IgE were excluded on the account of the small
number of cases. Relevant selection biases are unlikely as all
characteristics, progression-free survival and overall survival
appeared very similar in the selected group and in the group for
whom some data were missing. For the interpretation of Table
3, if the 95% confidence interval for the hazard ratio or the odds
ratio includes the value 1 the effect of the factor is not statistical-
ly significant at the 5% level; while intervals all above or all
below 1 indicate respectively significant risk/protective factors.
The size of the effect is proportional to the deviation from 1. All
analyses were carried out using SPSS statistical software (version
12.0.1) except the analyses of cumulative incidence curves,
which were carried out using the CMPRSK package in R 2.4.1. 
Results
Characteristics of the myeloma subgroups
The patients’ characteristics at diagnosis are shown in
Table 1, with percentage availability of results for each
variable shown. In most statistical comparisons the
IgE/IgM group was omitted to avoid invalidating the
analyses. Comparison with common myelomas showed a
statistically significant excess of male patients with IgD,
IgE and IgM myeloma, more advanced Salmon Durie
stage, and a greater degree of bone involvement. In IgD
myeloma the κ:λ ratio was reversed (P=0.001).  It can be
seen that more patients with IgE myeloma also had an
excess of λ light chains while those with IgM myeloma
had the usual ratio of κ/λ. Among the patients with non-
secretory myeloma there was a higher percentage of
patients with stage III myeloma at diagnosis (P<0.001),
which may be related at least in part to a significant
increase in patients with major bone abnormalities at diag-
nosis (P<0.001) and the difficulty in diagnosing this form
of myeloma due to the absence of a typical ‘spike’ on pro-
tein electrophoresis.  
Reviewing the discrete variables it can be seen that
patients with IgD myelomas were marginally younger,
had a lower M protein level and higher albumin concen-
tration than those with common myelomas whereas these
patients had a significantly lower hemoglobin concentra-
tion and higher β2 microglobulin and serum creatinine lev-
els (all comparisons, P<0.0001). While patients with non-
secretory myeloma were also significantly younger than
C. Morris et al.
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Table 2. Comparison of disease response to therapy and engraftment between patients with IgD, IgE, IgM and non-secretory myelomas and those with
with common types of myeloma.
Characteristic Common myelomas IgD IgE IgM NS Myeloma
% % available Data % available Data Info Data Info Data % available
available available
Disease response Complete remission** 11.9 94.7 20.1 95.8 33.3 92.3 7.8 88.9 28.9 91.0%
at conditioning Partial remission 69.0 65.8 58.3 68.8 53.9
No response 12.3 8.0 8.3 17.2 10.4
Relapse, progression, 6.8 6.1 0.0 6.3 6.8
untreated and other
Performance status Good 93.8 64.7 93.7 59.1 100.0 76.9 94.9 81.9 93.7 72.8%
at transplant Poor 6.2 6.3 0.0 5.1 86.3
Disease response CR** 28.2 89.5 43.8 88.8 60 76.9 33.9 86.1 48.8 84.6
post-transplant CR or PR* 61.8 66.0 70 53.2 66.3
Engraftment Engrafted 97.6 97.3 97.5 96.0 100 92.3 98.5 98.2 98.0
Not engrafted 1.8 1.7 0 0 1.3
Dead without engraftment 0.6 0.8 0 1.5 0.5
Median† survival Months 62.3 43.5 33.4 44.7 64.6
Confidence interval 60.5-64.1 36.1-50.9 20.1-46.8 33.8-55.6 57.3-71.8
Median progression Months 27.4 23.7 27.8 22.8 33.6
free survival†† Confidence interval 26.7–28.0 20.4-26.9 19.9-35.8 19.3-26.4 29.4-37.8
Second stem cell Autologous 6838 90 4 23 268
transplantation N=7223 (32.9%) (23.7%) (30.8%) (31.9%) (27.4%)
Allogeneic 1180 20 1 3 50
N=1254 (5.7%) (5.3%) (7.7%) (4.2%) (5.1%)
Median time 
to 2nd transplant (days) 128 112 143 208 132
* P=0.018; **P=0.001; †P=0.0003 for IgD/non-secretory; ††P=0.0001 for IgD/non-secretory.
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those with common myeloma, with significantly higher
albumin and hemoglobin levels, their serum creatinine
was significantly lower (all comparisons, P=0.0001). The
IgM patients had the highest calcium levels and the lowest
hemoglobin concentrations, but their levels of β2-
microglobulin, albumin and creatinine did not differ great-
ly from those of patients with common myelomas. The
time from diagnosis to transplantation was similar for
patients with common, IgE/IgM or non-secretory myelo-
ma while the median time to transplantation of the
patients with IgD myeloma was approximately 3 weeks
shorter.  It should be noted that while the P values for all
these differences are highly statistically significant, not all
are of biological significance, on account of the number of
patients analyzed. Furthermore, the numbers of IgE
patients for whom some of the data are reported are too
low to allow any conclusions to be drawn. The median
time to transplantation suggests that most patients were
transplanted as part of their first-line therapy but this was
not specified.
Transplant-related variables
Table 2 shows the transplant-related variables including
graft type, use of TBI and conditioning regimens. While
the differences in the use of stem cells other than periph-
eral blood stem cells were small, there were small increas-
es in the proportion of bone marrow cells used in the IgE
and IgM groups. It can be seen that there was greater use
of TBI, either alone or in conjunction with melphalan,
among patients with IgD myeloma, whereas patients with
IgM or non-secretory myeloma were less likely to receive
TBI; there were also some differences in the treatment
regimes used between patients with non-secretory myelo-
ma and those with common myeloma.  
Transplant outcomes
Comparisons of performance status and disease
response to induction therapy in patients undergoing trans-
plantation are shown in Table 2. Again the percentage
availability of data for each variable is shown where appro-
priate. There was no difference in the post-transplant
recovery between patients with IgD, IgE/IgM, non-secreto-
ry or common myeloma. Disease response in patients with
non-secretory myeloma was as defined by the reporting
institutions. Kaplan-Meier plots of overall survival, pro-
gression-free survival, relapse incidence and non-relapse
mortality are shown in Figure 1A-D, respectively. 
IgD myeloma
Patients with IgD myeloma appeared to have a better
response to therapy than those with common myeloma
with a greater proportion of the former patients being
transplanted in complete remission; this did not, however,
give rise to a difference in performance status. Similarly a
greater proportion of IgD myeloma patients achieved
complete remission after transplantation. There was no
difference in engraftment rates or in the times to neu-
trophil and platelet recovery post-transplantation.
While the median survival of patients with common
myeloma was 62.3 months (Figure 1A) (confidence inter-
vals shown in Table 2), the overall survival of patients
with IgD myeloma was significantly shorter, being 43.5
months (P=0.0001), despite the high complete remission
rate: this is presumably related to the high relapse rate in
patients with IgD myeloma (Figure 1C; P=0.0004). The
median progression-free survival was 27.4 and 23.7
months, respectively (P=0.017) (Figure 1B, confidence lim-
its in Table 2). Although the graphs must be interpreted
with caution, there appears to be plateau-like flattening of
the curve not only for common myeloma but also for IgD
myeloma.
IgM myeloma
Although the proportion of patients with IgM myeloma
achieving complete remission prior to transplantation was
the lowest of all the groups, the transplant appeared to have
a beneficial effect with the percentage of patients achieving
complete remission rising to 34% with a similar improve-
ment in the proportion of partial remissions.  Engraftment
appeared to be satisfactory in this group. Overall survival
and progression-free survival were markedly similar in
these patients to those in patients with IgD myeloma
(Figures 1A,B), but the small number of patients results in
wider confidence limits, as shown in Table 2.
Autologous transplantation in rare myelomas
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Table 3. Multivariate analysis of risk factors for outcome.
Overall survival Progression Relapse Non-relapse mortality CR CR + PR 
free survival versus <CR versus <PR
IgD versus common 1.03-1.68 1.01-1.49 1.04-1.56 0.55-1.70 1.49-2.65 0.95-1.76
IgM versus common 0.85-2.43 0.63-1.59 0.44-1.36 1.08-5.39 0.65-2.57 0.42-1.54
Non-secretory versus common 0.82-1.1 0.71-0.91 0.70-0.90 0.63-1.17 2.35-3.25 1.03-1.46
Age (+1 year) 1.01-1.22 1.01-1.02 1.008-1.012 1.006-1.021 0.98-0.99 0.98-0.99
Gender (female versusmale) 0.86-0.97 0.84-0.92 0.83-0.91 NS 1.07-1.23 1.00-1.14
Stage II versus I 1.06-1.33 0.13-1.21 1.02-1.21 0.91-1.43 0.96-1.24 0.93-1.18
Stage III versus I 1.47-1.79 1.28-1.48 1.25-1.45 1.30-1.92 0.84-1.06 0.79-0.97
Total body irradiation 1.16-1.37 1.03-1.18 NS 1.18-1.66 1.01-1.31 1.36-1.78
Diagnosis to transplant 
(+ 1 month) 1.002-1.004 1.001-1.003 1.001-1.003 1.002-1.006 0.995-0.999 0.997-0.999
Results shown are 95% confidence limits for odds ratio – results which do not bracket 1 are statistically significant. Thus for IgD versus control, IgD patients are at significantly
greater risk of overall survival, progression-free survival and relapse but not non-relapse mortality despite the fact the rate of CR is significantly higher than that for patients with
common myelomas (but not CR + PR). NS indicates not included in the analysis because not significant in the univariate analysis. CR: complete remission; PR: partial remission.
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IgE myeloma
Although the number of patients with IgE myeloma
was so small as to make any conclusion tentative, the
complete remission rate prior to transplantation was high-
est in this group. Despite this, the median overall survival
of patients in this group was the shortest of all groups
even though these patients’ progression-free survival was
similar or better than that of patients with IgG or IgM
myeloma. There did not appear to be any difficulty with
engraftment but the non-relapse mortality rate among
IgM/IgE myeloma patients was higher than that of
patients with any of the other types of myeloma (Figure
1D), although not statistically significantly so.  
Non-secretory myeloma
Table 2 shows that patients with non-secretory myelo-
ma had higher complete and complete + partial remission
rates than patients with common myeloma at mobiliza-
tion and conditioning although this did not result in a dif-
ference in performance status at transplantation. The
higher complete and complete + partial remission rates are
presumed to have contributed to the higher post-trans-
plant response rates, with an observed complete remission
rate of 48.8%, the highest of all groups excluding the small
IgE group. There was no overall difference in engraftment
data.  Figure 1A and 1B illustrate the superior overall sur-
vival (64.6 months) and progression-free survival (33.6
months) of patients with non-secretory myeloma (confi-
dence interval shown in Table 2); the progression-free sur-
vival of the patients with non-secretory myeloma was sta-
tistically significantly superior to that of patients with
common myeloma (P=0.0002); this was not, however,
reflected by a statistically superior overall survival.
Subsequent transplantation
Table 2 also shows the numbers and relative percent-
ages of patients with each type of myeloma proceeding to
a further transplant and the median time to the second
transplant (irrespective of type). It appears that patients
with common myeloma were most likely to receive a sec-
ond transplant and that IgD myeloma patients were least
likely; however, the differences were small and unlikely to
have affected the overall survival data. Curiously in
IgE/IgM myeloma patients the median time to a second
C. Morris et al.
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Figure 1. Outcomes of patients with rare myelomas: (A) overall survival; (B) progression-free survival; (C) relapse incidence; (D) non-relapse
mortality.
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transplant appeared longer. On account of the observa-
tional nature of this part of the study, the data are not
appropriate for further statistical analyses.
Adjusted analysis of response
Data from this analysis are summarized in Table 3.
Patients with ‘light chain type’ myeloma were excluded
from the analysis shown in the table but were included in
a companion analysis which showed little change in most
parameters. The hazard ratio for overall survival, progres-
sion-free survival and relapse among patients with IgD
myeloma was significantly adverse. When patients with
light chain type myeloma were included (data not shown)
the hazard ratio was reduced and lost its significance sug-
gesting that the adverse prognosis was related to the much
higher incidence of λ light chain in IgD myeloma, demon-
strated in Table 2.
The last two columns of Table 3 confirm that patients
with IgD or non-secretory myeloma had a significantly
higher probability of achieving complete remission than
that of the control group and that this was not a stage-
dependent effect. TBI usage and age were unfavorable fac-
tors while female gender was a favorable factor.
Somewhat surprisingly, when light chain status was
included in the analysis, this was found to be a favorable
factor (data not shown). This may be related to the high pro-
portion of patients with λ chain IgD myeloma achieving a
good response but having a poor overall survival due to
the high relapse rate in this group. However, when com-
plete and complete + partial remission rates were
reviewed, there were no differences between patients
with IgD, IgM, non-secretory or common myeloma in the
rate of achieving at least a partial remission.  Stage III
became an adverse factor but the effect of chain isotype
was lost. There were significant differences in the hazard
ratios for age, gender, TBI and time to transplantation but,
in general, these retained their impact on the model. In
producing this model it was noted that the use of TBI
overlapped completely with the year of transplant allow-
ing analysis of only one or other of these variables.
Discussion
Autologous transplantation with stem cells from bone
marrow or peripheral blood has been used to treat myelo-
ma for over two decades; the ability of cytokines to mobi-
lize stem cells in the peripheral blood has led to a huge rise
in the use of this mode of treatment.13 Initial impressions
of benefit shown in a single-center, non-randomized
series14 have now been confirmed in multicenter, prospec-
tive, randomized clinical trials.15,16 However, the numbers
of patients with rare myelomas, such as IgD, IgE and IgM
myeloma, in any such trial are usually insufficient to allow
any conclusion to be drawn regarding the outcome of
these patients, while patients with non-secretory myelo-
mas are often excluded from clinical trials because of the
difficulty in assessing response in this condition. We,
therefore, used the EBMT myeloma database containing
details from more than 22,000 patients to obtain informa-
tion on the outcome of transplantation in these rare con-
ditions and factors affecting the outcomes.
The overall message of this study is that patients with
rare myelomas (IgD, IgE and IgM myeloma) have a worse
prognosis than patients with the common myelomas. In
contrast, non-secretory myelomas should be considered
together with the common myelomas; although patients
with the non-secretory form have a better progression-
free survival (possibly related to the lack of the usual con-
ventional markers of disease progression in myeloma),
overall survival was only marginally better than that of
patients with common myelomas. On reviewing our data
in more detail, we confirmed that patients with IgD
myeloma had a significantly worse prognosis associated
with adverse prognostic factors, in keeping with previous
series describing this condition.17 This poor prognosis may
be related to the high proportion of patients with raised
proliferation rates combined with abnormal gene expres-
sion profiles demonstrated in a small group (n=12) of
patients with IgD myeloma.18 As with common myelomas
there was a small tail of long-term survivors confirming
the few case reports of prolonged survival in this condi-
tion19-21 and also in IgE myeloma.22 Of note, the proportion
of patients receiving TBI was higher among subjects with
IgD myeloma than among those with common myelomas
or all of the other rare myelomas and while this was asso-
ciated with a poorer outcome,13 it was not sufficient to
account for the 19-month difference in overall survival of
all patients with IgD myeloma. In fact patients with IgD
had higher rates of complete remission both before and
after transplantation, but unfortunately this did not trans-
late into a better overall survival due to their very high
relapse rate. 
In contrast, the non-secretory myelomas have both
favorable and adverse prognostic factors.23 The complete
remission rates in patients with this type of myeloma
appear to be very high, both before and after transplanta-
tion, possibly because of the lack of an identifiable para-
protein. The progression-free survival of patients with
non-secretory myeloma appears to be superior to that of
patients with common myeloma (P=0.0003), but there
was no difference in overall survival between the two
groups. The survival of patients with non-secretory
myeloma treated conventionally has been reported to be
similar to that of patients with common myeloma.1,24 In a
single-institution study of transplanted patients, those
with non-secretory myeloma had a significantly better
outcome than patients with all other myeloma types
although there were only six cases of non-secretory
myeloma in the series.25 The current much larger study
suggests that non-secretory myeloma behaves similarly to
common myelomas and should be treated similarly.
This retrospective analysis of ‘rare’ myelomas has
resulted in the production of the largest reported database
of rare myelomas to date. With the statistical power
obtained by large numbers there is the inevitable down-
side of poor reporting of certain parameters and the fact
that while differences may be shown to be statistically sig-
nificant, their biological significance may be of doubtful
importance.  Furthermore, while data such as overall sur-
vival and progression-free survival are robust, it must be
remembered that only the younger and fittest patients will
make it through to transplantation. While there is a sug-
gestion from our data that both IgD and non-secretory
myelomas tend to affect younger individuals, only 25% of
myeloma patients may undergo transplantion, as roughly
50% of all possible cases of myeloma are over the age of
68 years and co-morbid disease may be present in up to
50% of those below that age not undergoing transplanta-
tion.26
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It has recently been suggested that a very high incidence
of the t(11:14) (q13:q32) translocation is a hallmark of non-
secretory, IgE and IgM myelomas (but not of the IgD sub-
type),27 while Feyler et al. suggested that IgM myeloma is
characterized by a CD20–CD56–CD117– immunopheno-
type in addition to the t(11;14).28 This translocation in
patients with non-secretory myeloma may be related to the
significantly better progression-free survival but was not
translated into superior overall survival. In contrast, the sur-
vival of patients with IgM and IgE myelomas was very sim-
ilar to that of patients with IgD myeloma although the
small size of these groups means that differences were not
statistically significant. Of note there is no information on
survival in the report by Avet-Loiseau et al.27
The multivariate study adds support to the idea that
non-secretory myeloma is a disease of younger patients, in
keeping with other reports of a relatively young median
age of patients with this form of myeloma,7,9 which occurs
more often in males (male to female ratio, 3:2). Despite
their younger age, patients with non-secretory myeloma
present with more advanced disease and more bone
lesions than do patients with common myeloma (and
even IgD myeloma). In contrast, they have significantly
better median hemoglobin, albumin and creatinine levels
at presentation compared to patients with common
myeloma, implying that the major effect of non-secretory
myeloma is on the skeletal system rather than on other
organs. β2-microglobulin levels were similar to those in
patients with common myelomas. The difficulty in defin-
ing the level of response in non-secretory myeloma has
not been resolved in this study as we used the reporting
institutes’ assessments; in years to come serum free light
chain analysis29,30 and flow cytometry31 will bring some
objectivity to this difficult assessment.
Our study provides robust confirmation of the inversion
of the κ:λ light chain ratio in IgD myeloma with three-
quarters of patients having λ light chains. The data for IgE
myeloma show some similarity while the κ:λ ratio in IgM
myelomas is similar to that in common myelomas. For
IgD myeloma this would appear to be another adverse
prognostic factor to accompany a significantly higher
number of bone lesions and a greater proportion of
patients with stage III disease. A lower hemoglobin con-
centration and higher β2 microglobulin and creatinine lev-
els were also associated with poor prognosis. Due to the
poorer reporting of these data in the few patients with IgE
myeloma, no comments can be made about this group. 
Although we found that patients with rare myelomas
frequently have more adverse prognostic factors than
those with common myelomas and that, despite a higher
complete remission rate, this is reflected by a poor median
survival following transplantation, it should be noted that
the survival rates are significantly better, often more than
double, than those in the best historical series, even
though these series represent the outcomes of convention-
al therapy in patients of all ages.17 Two recent publications
also suggest a poor prognosis for patients with IgM
myeloma.28.32 Figure 1C shows that the relapse incidence
in patients with IgD myeloma was significantly higher but
associated specifically with the high incidence of λ chain
in this isotype (Table 1), while the incidence of non-
relapse mortality was much higher among patients with
IgE and IgM myelomas than among those with other
myelomas (Figure 1D).
In conclusion, this study suggests that patients with IgD,
IgE and IgM myelomas have adverse prognostic factors
and a worse survival than those with common myelomas
and non-secretory myeloma following transplantation.
Nevertheless, the survival of transplanted patients with
these rare myelomas is much better than anything previ-
ously recorded indicating that transplantation should not
be abandoned as a therapeutic modality. It remains to be
seen what new drugs, such as thalidomide, lenalidomide
and bortezomib, can do for these conditions.  
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